No description available.

Among abiotic stresses, salinity is considered the main limiting stress that negatively affects plant growth and reduces productivity worldwide. To overcome this challenge, a sustainable solution such as plant growth-promoting bacteria (PGPB) can be used to meet the increasing demand for food. The desert microbe Enterobacter sp SA187, an endophytic PGPB, induces salt tolerance in both model plant and crops. The interaction between SA187 and the host plant triggers the sulfur pathway in the bacteria which then provides multiple sulfur-containing compounds to its host plant. However, the molecular sensor of these compounds in the host plant is not known. Here, we show that SA187 activates the plant target of rapamycin (TOR) pathway. The beneficial effect of SA187 was lost in TOR mutants like raptor, and by the application of TOR inhibitor AZD8055. Next, we show that SA187 modulates the one- carbon (1C) metabolism of the host plant consisting of methionine and folate cycles. The beneficial effect of SA187 was compromised by using chemical inhibitors of folate cycle like Methotrexate (MTX) and Sulfadiazine (SDZ). The intermediates of the 1C metabolism like Homocysteine and S-adenosyl methionine (SAM) showed similar beneficial effects as SA187 colonized plants. Finally, we showed that SA187 enhances 1C metabolism activity by increasing methylation index (SAM/SAH ratio) in the plants. Taken together, we could show that host TOR-1C axis is essential for plant salt tolerance by SA187.

Germline mutations in the tumor suppressor gene PTEN cause PTEN Hamartoma Tumor Syndrome (PHTS). Pediatric patients with PHTS frequently develop lipomas. Treatment attempts with the mTORC1 inhibitor rapamycin were unable to reverse lipoma growth. Recently, lipomas associated with PIK3CA-related overgrowth syndrome were successfully treated with the novel PI3K inhibitor alpelisib. Here, we tested whether alpelisib has growth-restrictive effects and induces cell death in lipoma cells. We used PTEN-haploinsufficient lipoma cells from three patients and treated them with alpelisib alone or in combination with rapamycin. We tested the effect of alpelisib on viability, proliferation, cell death, induction of senescence, adipocyte differentiation, and signaling at 1–100 M alpelisib. Alpelisib alone or in combination with rapamycin reduced proliferation in a concentrationand time-dependent manner. No cell death but an induction of senescence was detected after alpelisib incubation for 72 h. Alpelisib treatment led to a reduced phosphorylation of AKT, mTOR, and ribosomal protein S6. Rapamycin treatment alone led to increased AKT phosphorylation. This effect could be reversed by combining rapamycin with alpelisib. Alpelisib reduced the size of lipoma spheroids by attenuating adipocyte differentiation. Since alpelisib was well tolerated in first clinical trials, this drug alone or in combination with rapamycin is a potential new treatment option for PHTS-related adipose tissue overgrowth.

No description available.

Indiana University-Purdue University Indianapolis (IUPUI) / Autophagy is a conserved cellular process that involves sequestration and degradation of cytosolic contents. The cell can engulf autophagic cargo (lipids, long-lived proteins, protein aggregates, and pathogens) through a double bound membrane called an autophagosome that fuses with a lysosome where hydrolases then degrade these contents. This process is one of the main defenses against starvation and is imperative for newborns at birth. Research on this process has increased exponentially in the last decade since its discovery almost a half a century ago. It has been found that autophagy is an important process in many diseases, continues to be at the forefront of research, and is clearly not fully understood. Our preliminary cell culture data in endothelial and epithelial cells show that a blockade of the de novo ceramide synthesis pathway, during treatment with an autophagy stimulus (cigarette smoke extract exposure), does not result in any reduction in autophagy or autophagic flux. Conversely, when acid sphingomyelinase (ASM) is pharmacologically inhibited, which prevents the generation of ceramide from sphingomyelin in an acidic environment, a profound increase in autophagy is observed. In this work, we hypothesize that (ASM) is an endogenous inhibitor of autophagy. ASM has two forms, a secreted form and a lysosomal form. N-terminal processing in the Golgi determines its cellular fate. In the lysosomal form, the phosphodiesterase is bound in the lysosomal membrane. The pharmacological inhibition mechanism is to release ASM from the membrane and allow other hydrolases to actively degrade the enzyme which, in turn, decreases the activity of ASM. This suggests that either the activity of ASM is a regulator of autophagy or that the presence of ASM, activity aside, is required for the lysosomal nutrient sensing machinery (LYNUS) to function properly. Here, we show that ASM is, in fact, an endogenous inhibitor of autophagy in vitro. The phosphorylation status of P70 S6k, a downstream effector of mammalian target of rapamycin (mTOR), which is part of the LYNUS, shows that dissociation of ASM from the membrane regulates mTOR and disturbs the LYNUS in such a manner as to signal autophagy.

Proteins in Escherichia coli were compared in terms of essentiality, centrality, and conservation. The hypotheses of this study are: for proteins in Escherichia coli, (1) there is a positive, measureable correlation between protein conservation and essentiality, (2) there is a positive relationship between conservation and degree centrality, and (3) essentiality and centrality also have a positive correlation. The third hypothesis was supported by a moderate correlation, the first with a weak correlation, and the second hypotheis was not supported. When proteins that did not map to orthologous groups and proteins that had no interactions were removed, the relationship between essentality and conservation increased to a strong relationship. This was due to the effect of proteins that did not map to orthologus groups and suggests that protein orthology represented by clusters of orthologus groups does not accurately dipict protein conservation among the species studied.

La rapamycine est un immunosuppresseur utilisé pour traiter plusieurs types de maladies dont le cancer du rein. Son fonctionnement par l’inhibition de la voie de Tor mène à des changements dans des processus physiologiques, incluant le cycle cellulaire. Chez Saccharomyces cerevisiae, la rapamycine conduit à une altération rapide et globale de l’expression génique, déclenchant un remodelage de la chromatine. Nous proposons que les modifications des histones peuvent jouer un rôle crucial dans le remodelage de la chromatine en réponse à la rapamycine. Notre objectif principal est d’identifier d’une banque de mutants d’histone les variantes qui vont échouer à répondre à la rapamycine dans une tentative de réaliser une caractérisation des modifications d’histone critiques pour la réponse à cette drogue. Ainsi, nous avons réalisé un criblage d’une banque de mutants d’histone et identifié plusieurs mutants d‘histone dont la résistance à la rapamycine a été altérée. Nous avons caractérisé une de ces variantes d’histone, à savoir H2B, qui porte une substitution de l’alanine en arginine en position 95 (H2B-R95A) et démontré que ce mutant est extrêmement résistant à la rapamycine, et non à d’autres drogues. Des immunoprécipitations ont démontré que H2B-R95A est défectueux pour former un complexe avec Spt16, un facteur essentiel pour la dissociation de H2A et H2B de la chromatine, permetant la réplication et la transcription par les ADN et ARN polymérases, respectivement. Des expériences de ChIP-Chip et de micropuce ont démontré que l’arginine 95 de H2B est requise pour recruter Spt16 afin de permettre l’expression d’une multitude de gènes, dont certains font partie de la voie des phéromones. Des évidences seront présentées pour la première fois démontrant que la rapamycine peut activer la voie des phéromones et qu’une défectuosité dans cette voie cause la résistante à cette drogue. / Rapamycin is an immunosuppressant used for treating many types of diseases such as kidney carcinomas. It works by inhibiting the Tor signaling pathway leading to changes in physiological processes, including cell cycle arrest. In Saccharomyces cerevisiae, rapamycin leads to a rapid and global alteration in gene expression, prompting chromatin remodeling. We propose that histone modification(s) might play a crucial role in remodeling of the chromatin in response to rapamycin. Our main objective is to identify from a histone mutant collection variants that fail to respond to rapamycin in an attempt to characterize histone modifications critical for this drug response. As such, we conducted a screen of the histone mutant collection and identified several hits that showed resistance to rapamycin. We characterized one of the histone variants, namely H2B, carrying alanine substitution at arginine 95 (H2B-R95A) and show that it is extremely resistant to rapamycin, but not to other drugs. Pull downs demonstrated that H2B-R95A was defective in forming a complex with Spt16, an essential factor that is required to disassociate H2A and H2B from the chromatin in order to allow replication and transcription by DNA and RNA polymerases, respectively. ChIP-Chip and microarray experiments showed that arginine 95 of H2B is required to recruit Spt16 to allow expression of several genes, a subset of which are involved in the pheromone signaling pathway. Evidence will be presented to show for the first time that rapamycin can activate the pheromone pathway and that defects in this pathway cause resistance to the drug.

Orientador: Luis Gustavo Modelli de Andrade / Resumo: Introdução: Os inibidores do alvo de rapamicina em mamíferos (mTORI) podem conferir vantagens cardioprotetoras. Em modelos animais, o mTORI pode prevenir a aterogênese pela regulação da homeostase do colesterol e pela redução da resposta inflamatória. Além disso, a administração de mTORI pode levar à redução da massa ventricular esquerda. O objetivo deste estudo é comparar a espessura médio intimal da carotída (cIMT) e a massa ventricular esquerda indexada (LVMi) entre o grupo de tacrolimus associado a micofenolato (grupo micofenolato) e tacrolimo associado a sirolimo (grupo sirolimo) em baixas doses. A cIMT é considerada um marcador substituto da aterosclerose. Métodos: Nós avaliamos a cIMT e a LVMi no início e aos 6 e 12 meses após o transplante renal. Foram randomizados prospectivamente todos os receptores de transplante renal com mais de 60 anos para um dos dois grupos: tacrolimus / sirolimus (n = 21) ou tacrolimus / micofenolato (n = 23). A cIMT foi avaliada por ultrassonografia na parede da artéria carótida comum e o LVMi pelo ecocardiograma. Resultados: Os níveis de colesterol total e de lipoproteína de alta densidade (HDL) foram maiores no grupo do sirolimus aos 6 e 12 meses. O cIMT diminuiu com o tempo aos 6 e 12 meses no grupo do sirolimus (p = 0,012); esta diminuição continuou a ser significativa em um modelo ajustado para idade, sexo, presença de diabetes, uso de estatina e tabagismo. Houve redução ao longo do tempo na massa ventricular esquerda indexada, mas não ... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Background: Mammalian target of rapamycin inhibitors (mTORI) may confer cardioprotective advantages. In animal models, the mTORI may prevent atherogenesis by the regulation of homeostasis of cholesterol and by a reduced inflammatory response. In addition, the administration of mTORI may lead to reduction of left ventricular mass. The aim of this study is to compare the carotid intima-media thickness (cIMT) and left ventricular mass index (LVMi) between de novo tacrolimus/mycophenolate and tacrolimus/sirolimus at low doses. The cIMT is considered a surrogate marker of atherosclerosis. Methods: We evaluated cIMT and LVMi at baseline and at 6 and 12 months after kidney transplantation. We prospectively randomly assigned kidney transplant recipients older than 60 years of age to one of two groups: tacrolimus/sirolimus (n=21) or tacrolimus/mycophenolate (n=23). The cIMT was evaluated by using ultrasound in the common carotid artery wall in both sides ant the LVMi by echocardiogram. Results: The total and high-density lipoprotein cholesterol levels were higher in the sirolimus group at 6 and 12 months. The cIMT decreased over time at 6 and 12 months in the sirolimus group (p = 0.012); this decrease continued to be significant in a model adjusted for age, sex, presence of diabetes, statin use and smoking. There was a reduction over time in LVMi, but there were no differences between groups suggesting absence of sirolimus class effect. Conclusions: The use of sirolimus plus tacrolimu... (Complete abstract click electronic access below) / Mestre

La voie de signalisation mTORC1 hypothalamique (mammalian target of rapamycincomplexe 1) intègre les signaux hormonaux et nutritionnels. La disponibilité des nutrimentsmodule les espèces réactives derivées de l’oxygène (ROS) qui régulent l’activité des neuronesà propiomélanocortine (POMC). La modulation de la prise alimentaire induite par les ROSpourrait impliquer mTORC1.Des souris C57Bl6J et wild-type (WT) ou invalidées pour S6K1 (S6K1-KO), principaleprotéine cible de mTORC1, ou invalidées pour raptor, protéine clé de mTORC1,sélectivement au niveau des neurones anorexigènes POMC (POMC-raptor-KO) ont ététraitées par injections intracérébroventriculaires (ICV) d’H2O2 ou d’honokiol (piégeur deROS), uniques ou combinées avec un inhibiteur de mTOR (rapamycine) ou un activateur demTOR (leptine).L’H2O2 ICV induit une augmentation de l’activité hypothalamique mTORC1, de l’activationneuronale du noyau arqué, de l’expression des ROS dans les neurones POMC, associée à unediminution de la prise alimentaire et du poids. Cet effet anorexigène est diminué chez lessouris S6K1-KO, chez les C57Bl6J après administration de rapamycine, et chez les POMCraptor-KO.L’honokiol ICV bloque l’effet anorexigène de la leptine, suggérant que cet effet soitdépendant des ROS. La leptine ICV entraine une augmentation des ROS dans les neuronesPOMC des souris C57Bl6J et POMC-raptor-WT, mais pas chez les POMC-raptor-KO.Nos résultats montrent que la régulation de la prise alimentaire induite par les ROS nécessiteune voie mTORC1 fonctionnelle et que l’effet anorexigène de la leptine nécessite uneaugmentation de ROS, mTORC1 dépendante, au niveau des neurones POMC. / The mechanistic target of rapamycin complex 1 (mTORC1) pathway is an importanthypothalamic integrator of nutrients and hormones. Nutrient availability also affects thereactive oxygen species (ROS) in propiomelanocortin (POMC) neurons and regulatesneuronal activity. We hypothesize that modulation of mTORC1 activity mediates ROS effectson food intake.To this purpose, C57Bl6J mice or WT mice and their KO littermates either deficient for themTORC1 downstream target S6K1 or for the mTORC1 component raptor specifically inPOMC neurons (POMC-raptor-KO) were treated with an intracerebroventricular (ICV)injection of the ROS producer H2O2 or the ROS scavenger honokiol, alone or in combinationwith the mTOR inhibitor rapamycin or the mTOR activator leptin.ICV H2O2 induced phosphorylation of S6K1 within the hypothalamus, increased expressionof c-fos, a marker of neuronal activity, in the arcuate nucleus and increased ROS in POMCneurons. These effects were associated with a significant decrease in food intake. Theanorexigenic effect of ICV H2O2 was not seen in S6K1-KO mice, in C57Bl6J mice cotreatedwith rapamycin (an mTOR inhibitor) and in POMC-raptor-KO mice.Similarly, ICV honokiol administration combined with a leptin injection blunted theanorexigenic effect of leptin, suggesting that leptin requires ROS formation to reduce FI. ICVadministration of leptin increased ROS in POMC neurons in C57Bl6J and POMC-raptor-WTmice, but not in POMC-raptor-KO mice.Our results demonstrate that ROS modulators require a functional mTORC1 pathway toregulate food intake and that leptin needs an mTORC1-dependent increase in ROS levels inPOMC neurons to decrease food intake.

Accelerated Adaptation through Stimulated Copy Number Variation in Saccharomyces cerevisiae Ryan Matthew Hull Repetitive regions of the genome, such as the centromeres, telomeres and ribosomal DNA account for a large proportion of the genetic variation between individuals. Differences in the number of repeat sequences between individuals is termed copy number variation (CNV) and is rife across eukaryotic genomes. CNV is of clinical importance as it has been implicated in many human disorders, in particularly cancers where is has been associated with tumour growth and drug resistance. The copper-resistance gene CUP1 in Saccharomyces cerevisiae is one such CNV gene. CUP1 is transcribed from a copper inducible promoter and encodes a protein involved in copper detoxification. In this work I show that yeast can regulate their repeat levels of the CUP1 gene through a transcriptionally stimulated CNV mechanism, as a direct adaptation response to a hostile environment. I characterise the requirement of the epigenetic mark Histone H3 Lysine 56 acetylation (H3K56ac) for stimulated CNV and its limitation of only working at actively transcribed genes. Based upon my findings, I propose a model for how stimulated CNV is regulated in yeast and show how we can pharmacologically manipulate this mechanism using drugs, like nicotinamide and rapamycin, to stimulate and repress a cell's ability to adapt to its environment. I further show that the model is not limited to high-copy CUP1 repeat arrays, but is also applicable to low-copy systems. Finally, I show that the model extends to other genetic loci in response to different challenging environments, such as formaldehyde stimulation of the formaldehyde-resistance gene SFA1. To the best of our knowledge, this is the first example of any eukaryotic cell undergoing genome optimisation as a novel means to accelerate its adaptation in direct response to its environment. If conserved in higher eukaryotes, such a mechanism could have major implications in how we consider and treat disorders associated with changes in CNV.